Evergrowth BioHealthcare Capital

Join us for our Evergrowth Biotech Weekly Recap, where we break down the latest development and breakthroughs, latest #FDA decisions, and upcoming events—all in one place! This week, we’re diving into: #Exelixis #EXEL and its billion-dollar #cabozantinib franchise, with an #FDA decision coming soon in April 2025 #BridgeBio #BBIO just secured European #approval for BEYONTTRA™, a game-changer in treating ATTR-CM! #TravereTherapeutics #TVTX is on track to submit a new drug application for #FILSPARI — potentially the first-ever approved treatment for a rare #kidney disorder! What do these breakthroughs mean for #investors? Watch the full video below and subscribe to our channel for weekly biotech insights! https://lnkd.in/eu9sDsGC Join Us at the Evergrowth #Annual Meeting! #Evergrowth BioHealthcare Capital will be having its Annual Meeting on March 29, 2025. This event promises to be an enriching experience filled with #insights, #networking opportunities, and updates on our latest initiatives and performance. Register here: https://lnkd.in/ewu5JAsN #Evergrowth #hedgefund #investors #biotech #market #stockmarket #stocks

🚀 Surpassing Our 70% Milestone 🚀 We’re proud to announce that we’ve surpassed the 70% return mark —proof that our growth-focused strategy is delivering results! 📈✨ While other benchmarks like #INDU #NBI, and #SPY are experiencing downward or sideways trends, #Evergrowth continues to break barriers with a strong uptrend! We are thrilled to share that Evergrowth has achieved a 70.55% return since inception, as of February 15, 2025. This milestone motivates us even more to keep pushing forward and aim even higher. 💡 If you are an accredited #investor who is passionate about saving lives while growing your #investment portfolio, Evergrowth Biohealthcare Capital can be a good fit for you. 👉 Click the Calendly link below or scan the QR code to schedule a free consultation and see why Evergrowth is the best partner for your success. https://lnkd.in/e8zkZG5A Join us at the Evergrowth #Annual Meeting! #Evergrowth BioHealthcare Capital will be having its Annual Meeting on March 29, 2025. This event promises to be an enriching experience filled with #insights, #networking opportunities, and updates on our latest initiatives and performance. Register here: https://lnkd.in/ewu5JAsN

🚀 Evergrowth Continues to Outperform the Market! 📈 As of February 13, 2025, our #performance continues to reflect our expertise in navigating market trends and seizing emerging opportunities. We are thrilled to share that Evergrowth has achieved a 69.02% return since inception, surpassing key #benchmarks like the #INDU, #NBI, and #SPY. Our commitment to identifying high-growth opportunities has allowed us to deliver results that consistently beat the market. 💡 If you are an accredited #investor who is passionate about saving lives while growing your #investment portfolio, Evergrowth Biohealthcare Capital can be a good fit for you. 👉 Click the Calendly link below or scan the QR code to schedule a free consultation and see why Evergrowth is the best partner for your success. https://lnkd.in/e8zkZG5A #Evergrowth #hedgefund #stockmarket #healthcare #biotech #market #investment

Cardiac amyloidosis is a condition affecting over 300,000 people globally with rogue proteins invading the heart. This condition has long been a diagnostic puzzle but hope is on the horizon! https://lnkd.in/eYcyYUX4 In case you missed it, the #FDA has approved #BridgeBio #BBIO# Acoramidis, also known as #Attruby, a transthyretin stabilizer revolutionizing care for ATTR-CM. And that’s not all! #Vutrisiran, a promising #RNA interference therapy, is making waves by reducing TTR production and #cardiac events for ATTR amyloidosis patients. These breakthroughs are saving lives—and driving innovation. If you are an accredited #investor who is passionate about saving lives while growing your #investment portfolio, Evergrowth Biohealthcare Capital can be a good fit for you. 👉 Click the Calendly link below or scan the QR code to schedule a free consultation and see why Evergrowth is the best partner for your success. https://lnkd.in/e8zkZG5A #Evergrowth #hedgefund #stockmarket #healthcare #FDA #biotech #market #investment

Evergrowth Biotech Weekly Recap (Feb 3-7, 2025): https://lnkd.in/eBs4h47p The biotech industry continues to evolve, bringing exciting developments in pharmaceuticals, M&A, and financial performances. Here are the updates from the past week: ✅ #VandaPharmaceuticals #VNDA & #AnaptysBio #ANAB An exclusive global license agreement for imsidolimab, an IL-36R antagonist, has been secured! With two completed Phase 3 trials for Generalized Pustular Psoriasis (GPP), Vanda is preparing for U.S. and EU regulatory submissions in 2025. ✅ #VikingTherapeutics #VKTX Following impressive Phase 2 results showing 14.7% body weight reduction, #Viking is set to initiate Phase 3 trials for VK2735 (#obesity treatment) in Q2 2025. The company also boasts a strong $903M cash position at year-end 2024. ✅ #2seventybio #TSVT Despite a 32% YOY drop in Abecma sales ($242M), the company is optimizing operations and expects quarterly breakeven by the end of 2025. 📅 Upcoming Catalysts: February 11-12: Oppenheimer Healthcare Life Sciences Conference – a major event with 140+ companies & $230B in market cap. February 14: GSK’s PDUFA date for its 5-in-1 meningococcal vaccine. #GSK At #Evergrowth BioHealthcare Capital, we’re tracking these innovations closely and how these bring investment opportunities. Stay tuned for next week’s updates on biotech breakthroughs! 👉 Click the Calendly link below or scan the QR code to schedule a free consultation and see why Evergrowth is the best partner for your success. https://lnkd.in/e8zkZG5A #Evergrowth #hedgefund #stockmarket #healthcare #FDA #biotech #market #investment

🚀 Evergrowth Continues to Outperform the Market! 📈 We’re thrilled to share our latest performance update: 65.87% return since inception—significantly outpacing benchmark indices! Our investment strategy focuses on high-growth opportunities, delivering strong results for our investors. 📅 Join Us at the Evergrowth Annual Meeting! We're inviting all investors and those interested in our fund to our Evergrowth Annual Meeting on March 29, 2025. Gain exclusive insights into our portfolio updates, strategies, and future outlook. Register here: https://lnkd.in/eqhnnxSc 👉 Click the Calendly link below or scan the QR code to schedule a free consultation and see why Evergrowth is the best partner for your success. https://lnkd.in/e8zkZG5A #Investing #Growth #StockMarket #Evergrowth #FinancialSuccess #hedgefund #healthcare #biotech #investment #Networking #Innovation #stocks #investors

Exciting Breakthroughs in the Biotech Space! 🚀 https://lnkd.in/eX67MzTz ✅ #VertexPharmaceuticals #VRTX FDA Approval for JOURNAVX (suzetrigine) – A game-changer in pain management, offering a non-opioid solution for moderate-to-severe acute pain. This is the first new pain medicine class in over 20 years, bringing hope to 80 million Americans annually. ✅ #VertexPharmaceuticals #VRTX CASGEVY’s NHS Reimbursement Agreement – A major step for CRISPR/Cas9 gene-editing therapy, now accessible to sickle cell disease (SCD) patients in England. Expanding gene therapy access is a leap forward in precision medicine. ✅ Upcoming Guggenheim SMID Cap Biotech Conference – A vital event on Feb 5-6, 2025, spotlighting small to mid-cap biotech innovations. A must-watch for investors and industry professionals! ✅ #Novartis #NVS FDA Advisory Meeting for FABHALTA (iptacopan) – Set for Feb 24, 2025, this oral treatment for C3 glomerulopathy (C3G) could bring new hope for patients battling this rare kidney disease. At Evergrowth BioHealthcare Capital, we’re tracking these innovations closely and how these bring investment opportunities. Stay tuned for next week’s updates on biotech breakthroughs! 👉 Click the Calendly link below or scan the QR code to schedule a free consultation and see why Evergrowth is the best partner for your success. https://lnkd.in/e8zkZG5A #Evergrowth #hedgefund #stockmarket #healthcare #FDA #biotech #market #investment

Join Us at the Evergrowth Annual Meeting! Evergrowth BioHealthcare Capital will be having its Annual Meeting on March 29, 2025. This event promises to be an enriching experience filled with insights, networking opportunities, and updates on our latest initiatives. Here's what you can look forward to: 📈 Fund Performance - Get updates on our investment strategies and results. 🚀 Insights into Emerging Biotech Opportunities - Learn about the latest trends and innovations. 🤝 Networking with Leaders and Investors - Get to know the team behind Evergrowth's success. Don't miss this chance to be part of a community driving growth and innovation! Feel free to invite your family, friends, or anyone in your circle who you think would benefit from attending. We look forward to seeing you and celebrating our collective growth and success at the Evergrowth Annual Meeting! Email us at info@evergrowthinvest.com to learn more about this event. #Evergrowth #AnnualMeeting #Biotech #Healthcare #Networking #Innovation #Investment #stocks #investors #stockmarter #investing #networking

🌟 A Look at Our Numbers 🌟 Evergrowth has achieved a 50.86% return since inception—outperforming major benchmarks like #SPY, #INDU, and #NBI! We focus on small cap, high-growth companies, helping investors leverage our edge to beat the stock market. 🚀 👉 Click the Calendly link below or scan the QR code to schedule a free consultation and see why Evergrowth is the best partner for your success. https://lnkd.in/eJt2HdBH #biotech #investing #hedgefund #stocks

Don’t miss out on our Evergrowth Biotech Weekly Recap!    From groundbreaking trials to regulatory milestones, here's what we will discuss: #VikingTherapeutics #VRTX initiated a Phase 2 trial for their weight-loss tablet VK2735—early results show up to 14.7% weight reduction! #Exelixis #EXEL is one step closer to FDA approval for their blockbuster drug, #Cabozantinib, to treat neuroendocrine tumors—stay tuned for April 2025. #Amgen's #AMGN KRAS mutation therapy has its PDUFA date set for January 17, 2025 And don’t miss the J.P. Morgan Healthcare Conference this January—where lots of companies will participate Click the link below for the full video and subscribe for weekly biotech insights! https://lnkd.in/eDwvZFSq #biotech #recap #conference #jpmorgan #healthcare #FDA